InnoCare Pharma Limited (SEHK: 9969)
Health Care · Biotechnology · CN
HK$14.27
-4.48% today · -20.8% 1Y
InnoCare Pharma Limited (SEHK: 9969) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.78B and employs 1,176 people.
Over the last twelve months the share price has lost 20.8%, trading between 9.65 and 20.18.
Tweenvest scores InnoCare Pharma Limited across four factors: quality 51/100, value 27/100, growth 100/100. Its strongest factor is growth.
9969 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.78B
- Revenue (TTM)
- $365.68M
- P/E
- 28.92
- EPS
- 0.43
- Dividend yield
- —
- Beta (5Y)
- 0.39
- 52-week high
- HK$20.18
- 52-week low
- HK$9.65
- Avg volume (3M)
- —
- Shares outstanding
- 1.70B
- Employees
- 1,176
- Next earnings
- —
About InnoCare Pharma Limited
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
- ISIN
- KYG4783B1032
- Founded
- 2015
- Listed since
- Mar 23, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.